A clinical trial to study the effect Of two drugs, oxybutynin and terazocin, on bladder function, in patients of Posterior Urethral Valve after Transurethral Fulguratio
Not Applicable
- Conditions
- Health Condition 1: Q642- Congenital posterior urethral valves
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Boys aged between three months to 12 years, who have undergone primary TUF of PUV
2.Post TUF MCU showing adequate fulguration
3.Baseline UDS abnormalities including increased voiding pressure, low bladder capacity, poor compliance with elevated leak point pressure, high PVR
Exclusion Criteria
1.Patients who have undergone vesicostomy or upper tract diversion
2.Patients post primary TUF with post-operative MCU suggestive of incomplete fulguration
3.Patients with a normal baseline UDS
4.Patients not willing to participate in the study
5.Presence of other urethral anomalies along with PUV
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method